Difference between revisions of "Loricrin (TG3)"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 57: | Line 57: | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Epidermal transglutaminase|*]] | [[Category:Epidermal transglutaminase|*]] | ||
Latest revision as of 12:04, 10 March 2015
| Loricrin (TG3) | |
|---|---|
| Substrate peptide name | Loricrin |
| Synonyms | - |
| Determination type | In situ/In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cornified envelope |
| Swissprot ID | P23490 |
| Reactive glutamines | Q3, Q6, Q10, Q153, Q156, Q215, Q216, Q219, Q225, Q303, Q305, Q306, Q308 |
| Reactive lysines | K4, K5, K88, K307, K315 |
| Substrate sequence | SYQKKQPTPQPPV
SGGSVKYSGGG FSGQAVQCQSY YVSSQQVTQTSCA APQPSYGGG CHQTQQKQAPTWPSK |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:2007607 |
| Notes | Residues in bold have been determined as in situ substrates of TG3 |
